Inflectra (Infliximab-dyyb) for Psoriasis

Overview
Inflectra is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of active psoriatic arthritis and chronic severe plaque psoriasis. In cases of plaque psoriasis, Inflectra may be considered when systemic therapy is warranted and other medications are less appropriate. Inflectra may be referred to by its drug name, infliximab-dyyb.

Inflectra is a biologic drug. It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Inflectra is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Inflectra binds to TNF-α and prevents it from signaling the immune system to attack the connective tissues.

Inflectra is a biosimilar of Remicade. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.

How do I take it?
Inflectra is administered as an intravenous infusion in a medical setting every eight weeks after initial loading doses.

Inflectra is available in vial form.

Side effects
The FDA-approved label for Inflectra lists common side effects including headache, infections, infusion reactions, and abdominal pain.

Rare but serious side effects listed for Inflectra can include blood disorders, severe infections, increased risk for certain types of cancer, hepatitis B virus (HBV), liver or heart failure, hypersensitivity, cardiovascular reactions, and the development of lupus-like syndrome or demyelinating disease such as multiple sclerosis.

For more details about this treatment, visit:

Inflectra — Pfizer
https://www.pfizer.com/products/product-detail/...